PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31271801-0 2019 Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives. Chalcone 79-87 monoamine oxidase B Homo sapiens 41-60 32705963-0 2021 Revealing the role of fluorine pharmacophore in chalcone scaffold for shifting the MAO-B selectivity: investigation of a detailed molecular dynamics and quantum chemical study. Chalcone 48-56 monoamine oxidase B Homo sapiens 83-88 29714148-5 2018 The MAO inhibitory properties of the chalcone derivatives were evaluated with the recombinant human MAO-A and MAO-B enzymes and the potencies were expressed as the IC50 values. Chalcone 37-45 monoamine oxidase B Homo sapiens 110-115 27662218-2 2016 These compounds are structurally related to series of heterocyclic chalcone derivatives which have previously been shown to act as MAO-B specific inhibitors. Chalcone 67-75 monoamine oxidase B Homo sapiens 131-136 27402375-6 2016 A molecular docking study revealed that the presence of a H-bond network in hydroxylated chalcone with the N(5) atom of FAD is crucial for MAO-B selectivity and potency. Chalcone 89-97 monoamine oxidase B Homo sapiens 139-144 34262643-7 2021 The main conclusion of this cell biology, biochemistry, and structural study is to highlights 13 as a chalcone derivative that is worth consideration for the development of novel MAO-B-selective inhibitors for the treatment of neurodegenerative diseases. Chalcone 102-110 monoamine oxidase B Homo sapiens 179-184 32583952-0 2020 1-[4-(morpholin-4-yl)phenyl]-5-phenylpenta-2,4-dien-1-one as a new potent and selective monoamine oxidase-B inhibitor with extended conjugation in chalcone framework. Chalcone 147-155 monoamine oxidase B Homo sapiens 88-107 29195801-5 2018 The Ki value of F1 is the lowest among the values of chalcone derivatives and furthermore lower than that (0.0079 muM) of the reversible MAO-B inhibitor, lazabemide, a marketed drug. Chalcone 53-61 monoamine oxidase B Homo sapiens 137-142 29697034-7 2018 The chalcone class of compounds is well known to potently inhibit MAO-B, while nitrocatechol derivatives (e.g. tolcapone and entacapone) are clinically used COMT inhibitors. Chalcone 4-12 monoamine oxidase B Homo sapiens 66-71 29697034-11 2018 CONCLUSION: This study shows that nitrocatechol derivatives of chalcone may act as COMT and MAO-B inhibitors, and proposes a general strategy for further enhancing MAO-B inhibition while retaining the potent COMT inhibition activity of this class. Chalcone 63-71 monoamine oxidase B Homo sapiens 92-97 29697034-11 2018 CONCLUSION: This study shows that nitrocatechol derivatives of chalcone may act as COMT and MAO-B inhibitors, and proposes a general strategy for further enhancing MAO-B inhibition while retaining the potent COMT inhibition activity of this class. Chalcone 63-71 monoamine oxidase B Homo sapiens 164-169 28577983-1 2017 The MAO-B inhibitory activity of chalcone (1, 3- diphenyl-2-propen-1-one) based compounds arise from its structural similarity with 1, 4-diphenyl-2-butene, a known MAO-B inhibitor. Chalcone 33-41 monoamine oxidase B Homo sapiens 4-9 28577983-1 2017 The MAO-B inhibitory activity of chalcone (1, 3- diphenyl-2-propen-1-one) based compounds arise from its structural similarity with 1, 4-diphenyl-2-butene, a known MAO-B inhibitor. Chalcone 33-41 monoamine oxidase B Homo sapiens 164-169 28577983-1 2017 The MAO-B inhibitory activity of chalcone (1, 3- diphenyl-2-propen-1-one) based compounds arise from its structural similarity with 1, 4-diphenyl-2-butene, a known MAO-B inhibitor. Chalcone 43-72 monoamine oxidase B Homo sapiens 4-9 28577983-1 2017 The MAO-B inhibitory activity of chalcone (1, 3- diphenyl-2-propen-1-one) based compounds arise from its structural similarity with 1, 4-diphenyl-2-butene, a known MAO-B inhibitor. Chalcone 43-72 monoamine oxidase B Homo sapiens 164-169 34397324-2 2021 Several functionalized chalcone derivatives were shown to have potential reversible MAO-B inhibitory activity, which have recently been reported from our laboratory. Chalcone 23-31 monoamine oxidase B Homo sapiens 84-89 34397324-3 2021 METHODS: With the experimental results of about 70 chalcone derivatives, we further developed a pharmacophore modelling, and 2D and 3D- QSAR analyses of these reported chalcones for MAO-B inhibition. Chalcone 51-59 monoamine oxidase B Homo sapiens 182-187 35156567-0 2022 Extended double bond conjugation in the chalcone framework favours MAO-B inhibition: A structural perspective on molecular dynamics. Chalcone 40-48 monoamine oxidase B Homo sapiens 67-72 35156567-2 2022 The design of recent inhibitor therapeutic agents of MAO-B involves conjugation and modification of a chalcone scaffold comprising two aryl or heteroaryl rings connected via a short spacer unit with rotatable bonds. Chalcone 102-110 monoamine oxidase B Homo sapiens 53-58 33921982-0 2021 Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies. Chalcone 9-17 monoamine oxidase B Homo sapiens 43-48 32705910-2 2020 In this study, a series of 1, 4-benzodioxan-substituted chalcone derivatives were designed, synthesised and evaluated for their inhibitory activity against human MAO-B (hMAO-B). Chalcone 56-64 monoamine oxidase B Homo sapiens 162-167 32705910-2 2020 In this study, a series of 1, 4-benzodioxan-substituted chalcone derivatives were designed, synthesised and evaluated for their inhibitory activity against human MAO-B (hMAO-B). Chalcone 56-64 monoamine oxidase B Homo sapiens 169-175 32705963-3 2021 Despite the large plethora of the design of new selective MAO-B inhibitors, the current paper illustrates the role and orientation of fluorine atom with remarkable MAO-B selectivity of three compounds (O23, O24 and O25), which differ from all other substituents encountered in the chalcone scaffolds is recently reported by our group. Chalcone 281-289 monoamine oxidase B Homo sapiens 58-63 32705963-3 2021 Despite the large plethora of the design of new selective MAO-B inhibitors, the current paper illustrates the role and orientation of fluorine atom with remarkable MAO-B selectivity of three compounds (O23, O24 and O25), which differ from all other substituents encountered in the chalcone scaffolds is recently reported by our group. Chalcone 281-289 monoamine oxidase B Homo sapiens 164-169 32723232-5 2020 CONCLUSION: The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD. Chalcone 68-76 monoamine oxidase B Homo sapiens 173-178 32299731-2 2020 Based on this, nitrocatechol derivatives of chalcone have been proposed to represent dual-target-directed compounds that may inhibit both MAO-B and COMT. Chalcone 44-52 monoamine oxidase B Homo sapiens 138-143